Compare Marsh & McLennan Companies, Inc. (MRSH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Neurocrine Biosciences Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MRSH | NBIX | |
|---|---|---|
Market Cap | $86.15B | $15.77B |
Sector | Financials | Health |
52-Week High | $207.02 | $185.50 |
52-Week Low | $157.32 | $123.10 |
Enterprise Value | $106.83B | $15.78B |
Dividend Yield | 2.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals, including consistent earnings beats, a 14.24% net income margin, and robust cash flow. Recent news highlights growth in healthcare consulting and cyber risk services, supporting revenue expansion.
Outlook remains positive with a consensus price target of $208.63, offering 15% upside. Risks include economic sensitivity and debt levels, but analyst sentiment leans bullish with 30% buy ratings. The stock presents a growth opportunity in professional services, backed by solid financials and strategic initiatives.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
